文献速递血栓与止血

伏司他替尼长期治疗成人免疫性血小板减少症:3期临床试验项目中的开放标签扩展研究

Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.
PubMed 文献 · Am J Hematol · 2019-03-13

两项随机双盲安慰剂对照研究显示伏司他替尼对长期免疫性血小板减少症(ITP)成人有效;随后的开放标签扩展(OLE)研究评估其长期安全性和疗效。共146例患者接受伏司他替尼(其中123例进入OLE),中位治疗6.7个月,27例(18%)达稳定缓解,64例(44%)达总体缓解,最常见不良事件为腹泻、高血压、恶心、鼻出血和肝功能异常。

要点

  • 146例接受伏司他替尼治疗,中位疗程6.7个月,最长至31个月未见新发或频率增加的不良事件。
  • 27例(18%)达稳定缓解,中位缓解持续时间>28个月,中位血小板计数89 000/μL。
  • 64例(44%)达总体缓解,中位缓解持续时间>28个月;71例TPO失败者中24例(34%)达总体缓解。

核心结论

  • 近半数患者达总体缓解,且多数缓解维持超过2年。
  • 治疗至31个月未见新发或频率增加的不良事件。

研究设计与样本

  • 随机双盲安慰剂对照研究后的开放标签扩展(OLE)研究。
  • 共146例患者接受伏司他替尼,其中123例进入OLE研究。
  • 随机试验中双盲接受伏司他替尼的缓解者继续原剂量100至150 mg每日两次;无缓解者接受100 mg每日两次共4周,第4周可增至150 mg每日两次。

主要发现

  • 基线中位ITP病程8年,中位血小板计数16 000/μL;既往治疗包括血小板生成素(TPO)类药物(47%)、脾切除(35%)和利妥昔单抗(32%)。
  • 27例(18%)达稳定缓解,中位缓解持续时间>28个月,中位血小板计数89 000/μL。
  • 64例(44%)达总体缓解(含稳定缓解者),中位血小板计数63 000/μL,中位缓解持续时间>28个月。
  • 71例既往TPO类药物失败者中24例(34%)达总体缓解。
  • 最常见不良事件为腹泻、高血压、恶心、鼻出血和肝功能检查异常;多数为轻/中度,经减量、暂停给药和/或辅助用药后缓解或得到控制。

关键数值与推荐

  • 稳定缓解:随机试验中4/6次双周访视或OLE研究中2/3次每月访视血小板计数≥50 000/μL。
  • 总体缓解:第1至12周期间至少1次血小板计数≥50 000/μL。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Two randomized, double-blind, placebo-controlled studies demonstrated responses (≥50 000/μL) to fostamatinib in adults with long-standing immune thrombocytopenia (ITP). The long-term safety and efficacy of fostamatinib were evaluated in a follow-on, open-label extension (OLE) study. Patients received double-blind fostamatinib in the randomized trials, and responders continued the same dose, 100 to 150 mg BID, in the OLE study. Nonresponders received 100 mg BID for 4 weeks and could escalate to 150 mg BID at week 4. Endpoints included stable response, platelet count ≥50 000/μL at 4/6 biweekly (randomized trials) or 2/3 monthly visits (OLE), and overall response, ≥1 platelet count ≥50 000/μL during weeks 1 to 12. A total of 146 patients received fostamatinib including 123 in the OLE study. Median treatment duration was 6.7 months. Baseline median ITP duration was 8 years and median platelet count was 16 000/μL; prior treatments included thrombopoietic (TPO) agents (47%), splenectomy (35%), and rituximab (32%). Twenty-seven (18%) patients achieved a stable response with median duration of >28 months and a median platelet count of 89 000/μL. Sixty-four (44%) patients achieved an overall response (including stable responders) with a median platelet count of 63 000/μL and a median response duration of >28 months. Twenty-four of 71 (34%) patients who had failed TPO agents achieved overall responses to fostamatinib. The most common adverse events (AEs) were diarrhea, hypertension, nausea, epistaxis, and abnormal liver function tests. Most AEs were mild/moderate and resolved or were managed with dose reduction, dose interruption, and/or secondary medication. Almost half of the patients achieved an overall response, and most of these maintained their responses for >2 years. No new or increased frequency of AEs was seen at up to 31 months of treatment.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Bussel JB, Arnold DM, Boxer MA, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol. 2019. PMID: 30784097. doi:10.1002/ajh.25444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。